EW Healthcare Partners (EWHP) has held a final close of EW Healthcare Partners Fund 2 LP (Fund 2) with $745 million of capital. The new fund closed above its $650 million target.
Fund 2 will make minority or majority investments in US or Europe-based commercial-stage healthcare companies in the pharmaceutical, medical device, diagnostics, and technology-enabled services sectors.
“We are primarily looking for middle-market companies that have revenues of $20 million to $200 million and the potential to grow at around a 20% annual revenue growth rate for several years,” said Petri Vainio, managing director and chairman of EWHP’s executive committee. “We believe our healthcare expertise and team of experienced operating partners and senior advisors provide us with the platform to attract and add value to the types of healthcare companies that Fund 2 is targeting.”
“Our approach is hands-on, long-term oriented, highly collaborative and focused on value creation,” said Marty Sutter, co-founder and chairman of EWHP’s investment committee. “Our earlier fund successfully invested in several promising healthcare companies, and we look forward to endeavoring to build another portfolio of successful healthcare companies in Fund 2. Our goal is to provide capital that can drive revenue growth by expanding a sales force, expanding the geographic territory or countries where the products are sold, acquiring complementary products or companies, and/or developing and launching new products.”
Since its founding in 1985, EWHP (originally called Essex Woodlands) has raised just less than $4 billion in capital and invested in more than 150 healthcare companies. EWHP’s earlier fund, Essex Woodlands Fund IX LP, closed in October 2016 at $543 million. The firm’s team is made up of 20 senior investment professionals and 10 experienced healthcare executives. EWHP has offices in Palo Alto, Houston, New York, and London (www.ewhealthcare.com).
© 2019 Private Equity Professional | August 23, 2019